title: Clinical and angiographic outcome after endovascular management of giant intracranial aneurysms.
abstract: OBJECTIVE
  Giant (>or=25 mm) intracranial aneurysms (IA) have an extremely poor natural history and continue to confound modern techniques for management. Currently, there is a dearth of large series examining endovascular treatment of giant IAs only.
  
  
  METHODS
  We reviewed long-term clinical and radiological outcome from a series of 39 consecutive giant IAs treated with endovascular repair in 38 patients at 2 tertiary referral centers. Data were evaluated in 3 ways: on a per-treatment session basis for each aneurysm, at 30 days after each patient's final treatment, and at the last known follow-up examination.
  
  
  RESULTS
  Ten (26%) aneurysms were ruptured. At the last angiographic follow-up examination (21.5 +/- 22.9 months), 95% or higher and 100% occlusion rates were documented in 64 and 36% of aneurysms, respectively, with parent vessel preservation maintained in 74%. Stents were required in 25 aneurysms. Twenty percent of treatment sessions resulted in permanent morbidity, and death within 30 days occurred after 8% of treatment sessions. On average, 1.9 +/- 1.1 sessions were required to treat each aneurysm, with a resulting cumulative per-patient mortality of 16% and morbidity of 32%. At the last known clinical follow-up examination (mean, 24.8 +/- 24.8 months), 24 (63%) patients had Glasgow Outcome Scale scores of 4 or 5 ("good" or "excellent"), 10 patients had worsened neurological function from baseline (26% morbidity), and 11 had died (29% mortality).
  
  
  CONCLUSIONS
  We present what is to our knowledge the largest series to date evaluating outcome after consecutive giant IAs treated with endovascular repair. Giant IAs carry a high risk for surgical or endovascular intervention. We hope critical and honest evaluation of treatment results will ensure continued improvement in patient care.
authors.affiliation: Department of Neurosurgery, Millard Fillmore Gates Hospital, Kaleida Health, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14209, USA.
authors.forename: Babak S
authors.initials: BS
authors.lastname: Jahromi
authors.forename: J
authors.initials: J
authors.lastname: Mocco
authors.forename: Jee A
authors.initials: JA
authors.lastname: Bang
authors.forename: Yakov
authors.initials: Y
authors.lastname: Gologorsky
authors.forename: Adnan H
authors.initials: AH
authors.lastname: Siddiqui
authors.forename: Michael B
authors.initials: MB
authors.lastname: Horowitz
authors.forename: L Nelson
authors.initials: LN
authors.lastname: Hopkins
authors.forename: Elad I
authors.initials: EI
authors.lastname: Levy
mesh_terms: D000328:Adult; D000368:Aged; D002533:Cerebral Angiography; D019299:Decompression, Surgical / Q000009:adverse effects / Q000295:instrumentation; D004621:Embolization, Therapeutic / Q000009:adverse effects; D017809:Fatal Outcome; D005500:Follow-Up Studies; D006801:Humans; D002532:Intracranial Aneurysm / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects / Q000295:instrumentation; D019736:Prostheses and Implants; D012086:Reoperation; D012189:Retrospective Studies; D015607:Stents; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects / Q000295:instrumentation